Related references
Note: Only part of the references are listed.Fingolimod targets cerebral endothelial activation to block leukocyte recruitment in the central nervous system
Yawei Zhao et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2018)
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis
Lenka Novakova et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis
Lenka Novakova et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation
Katja Thomas et al.
JOURNAL OF NEUROINFLAMMATION (2017)
Size-selective opening of the blood-brain barrier by targeting endothelial sphingosine 1-phosphate receptor 1
Keisuke Yanagida et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis
Shiri Blumenfeld et al.
JOURNAL OF AUTOIMMUNITY (2016)
Fingolimod Prevents Blood-Brain Barrier Disruption Induced by the Sera from Patients with Multiple Sclerosis
Hideaki Nishihara et al.
PLOS ONE (2015)
Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis
David Henault et al.
NEUROLOGY (2013)
S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis
Nagaja Capitani et al.
BLOOD (2012)
Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy
Jens Ingwersen et al.
CLINICAL IMMUNOLOGY (2012)
Progressive multiple sclerosis: pathology and pathogenesis
Hans Lassmann et al.
NATURE REVIEWS NEUROLOGY (2012)
Serum tight-junction proteins predict hemorrhagic transformation in ischemic stroke patients
Radoslaw Kazmierski et al.
NEUROLOGY (2012)
FTY720 Rescue Therapy in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis: Expression of Central Nervous System Genes and Reversal of Blood-Brain-Barrier Damage
Carolyn A. Foster et al.
BRAIN PATHOLOGY (2009)
Higher expression of BDNF receptor gp145trkB is associated with lower apoptosis intensity in T cell lines in multiple sclerosis
Lorenzo De Santi et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2009)
Tight junctions and the modulation of barrier function in disease
Carola Foerster
HISTOCHEMISTRY AND CELL BIOLOGY (2008)
S1P(1) receptor signaling overrides retention mediated by G alpha(i)-coupled receptors to promote T cell egress
Trung H. M. Pham et al.
IMMUNITY (2008)
Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubipuitinylation and proteasomal degradation of the receptor
Myat Lin Oo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis
Ernmanuelle Waubant
DISEASE MARKERS (2006)
The blood-brain barrier: an overview - Structure, regulation, and clinical implications
P Ballabh et al.
NEUROBIOLOGY OF DISEASE (2004)
Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination
J Kirk et al.
JOURNAL OF PATHOLOGY (2003)
MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals
F Cotton et al.
NEUROLOGY (2003)
Serum from patients with multiple sclerosis downregulates occludin and VE-cadherin expression in cultured endothelial cells
A Minagar et al.
MULTIPLE SCLEROSIS (2003)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
WI McDonald et al.
ANNALS OF NEUROLOGY (2001)
Medical progress: Multiple sclerosis.
JH Noseworthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
